Quarterly Result5 Nov 2025, 02:54 pm
Solara Active Pharma Sciences Q2'26 Performance Impacted by Short-term Disruptions; Revenue Down 10% YoY
AI Summary
Solara Active Pharma Sciences Limited's Q2'26 performance was impacted by short-term disruptions due to an unscheduled operational shutdown at Mangalore for facility upgradation. This resulted in delayed deliveries and reduced sales volumes, leading to a 10% YoY decrease in revenue. However, the company's long-term fundamentals remain strong, with a resilient operating model, robust compliance framework, and a diversified portfolio across key markets. Regulated markets constitute 75% of the total revenues in Q2'26.
Key Highlights
- Q2'26 revenue down by 10% YoY to INR 3,140 Mn
- Gross margin at 51%, up 50 bps YoY
- Operating costs impacted by one-time costs of ~INR 40mn due to operational shutdown
- EBITDA at INR 352 Mn (11.3%)
- Regulated markets constitute 75% of total revenues in Q2'26